Rubicon Genomics is a leader in the development of improved technologies for detecting the pattern of DNA methylation in cancer cells. Rubicon has developed a superior test to non-invasively diagnose cancer and other diseases using its proprietary MethylPlex™ technology to amplify the exceedingly small amounts of abnormally-methylated DNA that are released by diseased tissue into serum and urine. MethylPlex has proven sensitivity and simplicity advantages over current competitive tests for methylated DNA tumor markers. The increased technical sensitivity will enable earlier, more reliable non-invasive detection of disease as well as allow for more methylation markers to be assayed in a single test, thus increasing both diagnostic sensitivity and specificity. The increased simplicity of MethylPlex enables inexpensive, robust tests utilizing currently existing diagnostic platforms. Achievement of these sensitivity and simplicity milestones make MethylPlex the first cancer diagnostic tool to meet the performance
